SEC Form 10-Q filed by Atea Pharmaceuticals Inc.
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/13/2024 | $2.00 → $6.88 | Underweight → Equal-Weight | Morgan Stanley |
8/10/2023 | Neutral → Underweight | JP Morgan | |
3/2/2022 | $10.00 → $8.00 | Neutral | JP Morgan |
3/1/2022 | $10.00 → $9.00 | Market Perform | SVB Leerink |
2/16/2022 | $11.00 → $10.00 | Market Perform | SVB Leerink |
1/6/2022 | $14.00 → $7.00 | Equal-Weight → Underweight | Morgan Stanley |
11/18/2021 | Outperform → Mkt Perform | SVB Leerink | |
11/18/2021 | $11.00 | Outperform → Market Perform | SVB Leerink |
4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)